Nikolai Kley, Orionis Biosciences CEO

No­var­tis-part­nered Ori­o­n­is se­cures $55M to push cy­tokine pro­gram in­to clin­ic

In sev­en years, a small com­pa­ny has built two pro­grams in im­muno-on­col­o­gy and mol­e­c­u­lar glues and got it­self in­to a part­ner­ship with one of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.